1310OAdjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial

Published 2019 View Full Article

Authors

Keywords

Journal

ANNALS OF ONCOLOGY

Volume 30, Issue Supplement_5, Pages -

Publisher

Oxford University Press (OUP)

Online

2019-10-01

DOI

10.1093/annonc/mdz255

Ask authors/readers for more resources

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

ANNALS OF ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Create your own webinar

Ask a Question. Answer a Question.